Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy

Abstract

Rates of approval for PCSK9i therapy are low, even for patients who appear to meet labeled indications. Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant factor.